Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
10 nov. 2021 07h00 HE
|
Galera Therapeutics
Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in...
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
19 oct. 2021 07h00 HE
|
Galera Therapeutics
Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median...
Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
12 oct. 2021 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
14 sept. 2021 07h00 HE
|
Galera Therapeutics
Event to be webcast on Thursday, September 23 at 11:00 a.m. ET Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out...
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
08 sept. 2021 07h00 HE
|
Galera Therapeutics
Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate Hazard ratios better than 0.5 on all survival and tumor outcome...
Galera to Present at Three Upcoming Investor Conferences in September
07 sept. 2021 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
10 août 2021 07h00 HE
|
Galera Therapeutics
Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall...
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
28 juin 2021 07h00 HE
|
Galera Therapeutics
Topline data expected in the second half of 2021 Triggers $37.5M milestone payment from Blackstone Life Sciences MALVERN, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq:...
Galera to Present at the Jefferies Virtual Healthcare Conference
26 mai 2021 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
17 mai 2021 07h00 HE
|
Galera Therapeutics
Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial Triggers $20M milestone payment from Blackstone Life Sciences 160-patient randomized, multicenter,...